These innovative agents represent a significant progression in the therapy of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in lowering blood glucose levels. https://prestonzedv669604.ja-blog.com/39352769/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide